Mr. Moch has played an integral role in building several life science companies, having previously led Alteon Inc. and Biocyte Corporation as Chief Executive Officer. He also served as Managing Director, Healthcare Banking at ThinkEquity Partners. Mr. Moch was a co-founder and Vice President of The Liposome Company, Inc. (acquired by Elan), and earlier in his career, he was a management consultant with McKinsey & Company, Inc. He holds an A.B. degree in biochemistry from Princeton University and an MBA from the Stanford Graduate School of Business.
"I am honored to assume this responsibility as Chimerix is well positioned as an emerging leader in antiviral drug development. With a pipeline of potent antiviral medicines, a technology capable of radically improving the pharmacological properties of drug candidates, a chemical library generating NCEs and an outstanding scientific and clinical team, this is the right time to accelerate development and partnering activities," said Mr. Moch. "I look forward to the development of our lead clinical-stage candidates, CMX001 and CMX157, and to advancing promising new antiviral compounds into the clinic alone and in conjunction with future partners."
Dr. Painter led Chimerix as President and Chief Executive Officer since its founding in 2002. Dr. Painter has more than 31 years of experience in pharmaceutical development, having served as a founding member of the Triangle Pharmaceuticals management team, where he was Executive Vice President, Research and Development. Prior, he was Director of Chemistry and Director of Vir
|SOURCE Chimerix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved